“In August of this year, The Wall Street Journal reported that Judge Royce Lambert of U.S. District Court in Washington, D.C. had issued a preliminary injunction against federal funding for human embryonic stem cell research…However, on Monday, November 22, the U.S. Food and Drug Administration (FDA) lifted the clinical hold to clear Advanced Cell Technology’s (ACT) Investigational New Drug (IND) application and initiate a Phase I/II multicenter study, using retinal cells derived from human embryonic stem cells to treat patients with Stargardt disease…” To learn more about the upcoming stem cell trials aimed at curing blindness caused by Stargardt’s, click here.